Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$13.8M | -$19.1M | -$26.2M | -$32.7M | -$42.7M | -$55.7M | -$70.4M | -$101M | -$151M | -$393M |
| Net income | -$14.7M | -$20.6M | -$22.1M | -$25.8M | -$39.5M | -$55.0M | -$68.9M | -$85.9M | -$110M | -$360M |
| EPS (diluted) | -$0.90 | -$0.79 | -$0.38 | -$0.36 | -$0.54 | -$0.71 | -$0.90 | -$0.91 | -$1.01 | -$3.19 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.1M | -$14.8M | -$18.8M | -$24.8M | -$21.8M | -$47.6M | -$48.4M | -$73.4M | -$87.8M | -$279M |
| Share buybacks | $229.00 | — | — | — | — | — | $6.79M | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.08M | $8.99M | $24.8M | $8.38M | $29.1M | $26.4M | $36.6M | $55.5M | $26.7M | $166M |
| Total assets | $14.5M | $22.1M | $302M | $284M | $257M | $211M | $169M | $368M | $908M | $716M |
| Total liabilities | $6.49M | $8.66M | $4.56M | $7.14M | $12.2M | $8.78M | $23.2M | $20.1M | $28.0M | $76.7M |
| Shareholders' equity | $8.04M | $13.5M | $298M | $277M | $244M | $202M | $145M | $348M | $880M | $639M |
| Retained earnings | -$60.3M | -$80.9M | -$103M | -$129M | -$168M | -$223M | -$292M | -$378M | -$488M | -$848M |
| Shares (wtd avg diluted) | 20.8M | 35.8M | 71.7M | 72.4M | 73.2M | 77.2M | 76.8M | 94.3M | 109M | 113M |
Every figure is extracted from Viking Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.